Summary
Guardant Health, Inc. reported a significant increase in revenue for the second quarter and first half of 2025, driven by strong performance in its Oncology and Biopharma and Data segments. Total revenue for the three months ended June 30, 2025, was $232.1 million, up 31% year-over-year, and for the six months ended June 30, 2025, revenue reached $435.6 million, a 26% increase. The company also saw initial revenue from its newly launched Shield screening test. Despite revenue growth, Guardant Health continued to incur net losses, with a loss of $99.9 million for the quarter and $195.1 million for the first half of the year. The company's cash position remains robust with $735.5 million in cash, cash equivalents, and restricted cash as of June 30, 2025, providing ample liquidity for over 12 months. Key developments include the expanding commercial reach of the Shield test, which received National Comprehensive Cancer Network guideline inclusion and met Medicare coverage requirements, alongside continued investment in research and development. The company also successfully managed its debt structure by completing a note exchange transaction in February 2025, which retired a portion of its 2027 notes and resulted in a gain on extinguishment. Management anticipates continued investment in sales and marketing to drive adoption and expansion, particularly with the Shield product line and international growth initiatives.
Financial Highlights
55 data points| Revenue | $232.09M |
| Cost of Revenue | $81.20M |
| Gross Profit | $150.88M |
| R&D Expenses | $87.45M |
| Operating Expenses | $338.50M |
| Operating Income | -$106.41M |
| Interest Expense | $983K |
| Net Income | -$99.90M |
| EPS (Basic) | $-0.80 |
| EPS (Diluted) | $-0.80 |
| Shares Outstanding (Basic) | 124.11M |
| Shares Outstanding (Diluted) | 124.11M |
Key Highlights
- 1Total revenue for Q2 2025 increased by 31% to $232.1 million, and by 26% to $435.6 million for the first half of 2025, indicating strong top-line growth.
- 2The Oncology and Biopharma and Data segments continue to be the primary revenue drivers, showing year-over-year growth of 22% and 28% respectively for Q2 2025.
- 3Significant progress in the Shield screening test, with initial revenue generated in Q2 2025 and inclusion in NCCN guidelines and Medicare coverage, supporting future growth potential in early cancer detection.
- 4Despite revenue growth, the company reported net losses of $99.9 million for Q2 2025 and $195.1 million for the first half of 2025, consistent with its growth and investment strategy.
- 5Guardant Health maintains a strong liquidity position with $735.5 million in cash, cash equivalents, and restricted cash as of June 30, 2025, sufficient for more than 12 months of operations.
- 6The company completed a note exchange in February 2025, reducing its 2027 convertible notes by $659.3 million and recognizing a $13.7 million gain on extinguishment.
- 7Operating expenses, particularly sales and marketing, increased substantially (46% for Q2 2025) due to commercial expansion and product launch activities, reflecting ongoing investment in growth.